BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
화요일, 9월 29

CRISPR Therapeutics AG

CRSPNASDAQ
Trade with Public
Trade with Public
$54.09
-0.14-0.26%
가까이에: Sep 28, 5:00 PM EST
$54.29
0.200.37%
시간외: 7:46 PM EST
개요뉴스실적 전망이벤트목표가재무심리지분 현황비교옵션주식 보고서

CRISPR Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for CRISPR Therapeutics (CRSP).

Price Target Range — 12 Quarters

Analyst Consensus — 23 Analysts

2S.Buy
11Buy
9Hold
1Sell
Consensus RatingBuy# Analysts23Avg. Consensus PT$72Upside to Avg. PT+33.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →
DateFirmAnalystActionRating ChangePrice Target
Aug 31, 2026CitizensSilvan TurkcanMaintainedMarket Outperform$80
Aug 31, 2026NeedhamGil BlumMaintainedBuy$82
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Citizens Reiterates Market Outperform on CRISPR Therapeutics, Maintains $80 Price Target

Citizens analyst Silvan Turkcan reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Market Outperform and maintains $80 price target.
Benzinga Newsdesk

PRO
Needham Reiterates Buy on CRISPR Therapeutics, Maintains $82 Price Target

Needham analyst Gil Blum reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and maintains $82 price target.
Benzinga Newsdesk

PRO
Citizens Reiterates Market Outperform on CRISPR Therapeutics, Maintains $80 Price Target

Citizens analyst Silvan Turkcan reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Market Outperform and maintains $80 price target.
Benzinga Newsdesk

PRO
Citigroup Maintains Buy on CRISPR Therapeutics, Raises Price Target to $88

Citigroup analyst Yigal Nochomovitz maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and raises the price target from $82 to $88.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on CRISPR Therapeutics, Maintains $80 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and maintains $80 price target.
Benzinga Newsdesk

PRO
Citizens Reiterates Market Outperform on CRISPR Therapeutics, Maintains $80 Price Target

Citizens analyst Silvan Turkcan reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Market Outperform and maintains $80 price target.
Benzinga Newsdesk

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

시장 데이터 제공 Benzinga API

BenzingaBenzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved